Page 2,278«..1020..2,2772,2782,2792,280..2,2902,300..»

California Stem Cell Agency’s $150,000 Search for Its Financial Future

Posted: August 25, 2013 at 2:57 am

A San Francisco consultant, who is
often known as an “economic therapist,” has been selected to
devise a “strategic road map” for the financial future of the $3
billion California stem cell agency.
James Gollub: 'economic therapist'
Gollub Associates photo
James Gollub, managing director of the
firm bearing his name, is under a $150,000 contract to lay out by
this fall a detailed plan for the agency. The nine-year-old research
effort is scheduled to run out of money for new awards in 2017.
Gollub was selected after the agency
posted a request for proposals (RFP) last spring. The RFP assumed an
additional $50 million to $200 million in a onetime “public
investment.” The RFP also assumed additional private funding of a
yet-to-be-determined nature.

“A leading expert in innovation
bridge building....
“Global experience assisting
universities, institutes, government agencies and public-private
partnerships link innovation sources to innovation
seekers.
“Committed to the goal of increasing flow of needed
solutions, optimizing financial returns and sustainable economic
impacts from innovation.”

Gollub's current firm dates back to
March of this year. His Linked In profile says,

“James Gollub Associates
(JGA) LLC was launched to build on 36 years of Gollub’s
professional research and consulting experience. That experience
began with 16 years at SRI International, three years at
DRI/McGraw-Hill, five years at IDeA, nine years at ICF International
and three years with E-Cubed Ventures LLC. During that
time Gollub has worked globally to deliver
economic strategies for over 30 national, state and metropolitan
regions, develop strategies to accelerate growth of new industries
(clusters), plan public and private R&D institutes and advise on
over 15 science and technology parks.”

The need for a financial transition plan for CIRM was publicly identified as long ago as 2009 by the Little Hoover Commission in its lengthy study and has been reiterated periodically by other bodies since then. Under the terms of Prop. 71, which created the agency, CIRM has only  a 10-year authority to issue state bonds, the borrowed funds that have sustained the research effort. Legal maneuvering blocked the issuance of bonds until 2007.

The California Stem Cell Report asked
the stem cell agency on May 31 for a copy of Gollub's response to the
RFP. Yesterday we asked for a copy of the contract with Gollub. Those
documents will be published when they are received.
Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/tncFJBJJM5I/california-stem-cell-agencys-150000.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Stem Cell Agency’s $150,000 Search for Its Financial Future

New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency

Posted: August 25, 2013 at 2:57 am

The $3 billion California stem cell
agency wants to recruit major biotech and venture capital firms to
help provide tens of millions of dollars in research awards to
California enterprises.
It's part of a move to “jump start”
partnerships in a relatively new, $80 million, business-friendly program that is aimed at pushing therapies into the
marketplace. The recruitment plan will come before the agency's governing board at its meeting next Wednesday in San Diego. 
Participating companies will have a
special relationship with the state agency, including early input
into concept funding proposals prior to their being presented to the
agency's governing board. The “industry collaborators” will also
be able to attend agency workshops and meetings involving
hundreds of grant recipients. Presumably other, non-collaborating
firms would be barred.
Other provisions of the plan call for
special event-hosting arrangements aimed at creating more
collaborations and posting of information from the selected
collaborators on the CIRM website.
According to a CIRM staff document, the
initiative would be limited to biotech and pharmaceutical firms with
a market capitalization of at least $500 million and “qualified
venture capital firms.” The document did not define what a
“qualified a venture capital firm” is. The document also appeared
to bar participation of privately held firms because of the “market
capitalization” criteria, which typically uses a formula involving
publicly traded shares.
Elona Baum, the agency's general
counsel and vice president, business development, said in a statement
provided to the California Stem Cell Report,

“This is aimed at trying to jump
start the creation of the partnerships that are required to satisfy
the commercial validation requirements of the Strategic Partnership
Funding Initiative so that timelines are better synced-up as between
our review and approval cycles for the Strategic Partnership RFAs and
the lengthy time required for investors to conduct due diligence and
negotiate an agreement with prospective applicants to Strategic
Partnership RFAs.  CIRM's independent review and approval
remains the same and is wholly independent. While there may be input
given to a particular RFA it only at the high level concept stage and
of course CIRM has no obligation to agree. In the context of the
Strategic Partnership awards, CIRM wants to fund innovative high
quality science that has attracted additional  investors.
 Investors will help leverage CIRM fund and will be an important
source of future funding to further the project.”  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/ZtmnBmRh5K0/new-ties-to-big-pharma-and-venture.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency

A $2 Million Bill: Outside Contracting by California Stem Cell Agency

Posted: August 25, 2013 at 2:57 am

The $3 billion California stem cell
agency this week posted a list of its outside contractors, who range
from a a $25,000 stem cell licensing consultant to a $550,000-a-year law firm.
The agency expects to spend $2
million during 2013-14 on outside contracting, down from $2.9 million
in 2012-13. This week's report covers the 2012-13 year.
Outside contracting is the second
largest item in the agency's budget, which is slated to spend $17.4
million this fiscal year for operational expenses, up 5 percent
from last year's spending. The largest amount, $12.2 million, goes
for salaries and benefits. (For more on the budget, see here, here
and here.)
Topping the contractor list is the law
firm of Remcho, Johansen & Purcell of San Leandro, Ca., which had
the $550,000 contract. CIRM, as the agency is known, reported that Remcho came in under
budget by $95,595. That contrasts to some previous years when the
firm, which has represented the stem cell agency since its inception,
required additional cash on top of its original contract. James
Harrison of the Remcho firm is its face at the agency and is
designated as the outside counsel to the agency's governing board. In
all, the agency is slated to spend $2.2 million on legal expenses,
including in-house work.
David Earp is the stem cell licensing
contractor. He was paid only $13,125 on his $25,000 contract during
2012-13. It is unclear whether he will be paid the $11,875 balance.
Earp was chief patent counsel and senior vice president for business
development for Geron before it dropped its stem cell program. Earp was heavily involved in the $25 million loan that CIRM made to Geron in 2011. In
February 2008, he testified before CIRM about its then proposed loan
program.
The list of contractors included
$200,000 to the AlphaMed Press of Durham, N.C., as seed funding for a
stem cells translational journal, $156,434 to Hyatt Hotels for the
meeting of CIRM grant recipients, $250,000 to Kutir Corp. of Newark, Ca., for
informational technology services and $290,000 to the Mitchell
Group of Woodland Hills, Ca., also for information technology services.
The list of contractors will be
presented to the CIRM governing board at its meeting next week. The
list does not usually trigger any significant discussion.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/5UwFuEaKpJM/a-2-million-bill-outside-contracting-by.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on A $2 Million Bill: Outside Contracting by California Stem Cell Agency

California Stem Cell Agency Spending: Where the Money Is Going

Posted: August 25, 2013 at 2:57 am

Analysis of CIRM funding by Pat Olson, executive director of CIRM scientific activities July 2013
The California stem cell agency will
have committed $472 million to translational research – a key to
commercializing stem cell therapies – if it awards the full $70
million in new grants and loans slated to come before its governing
board next week.
The nearly $500 million will amount to
about 17 percent of its funding so far, according to an analysis last
month by Pat Olson, the agency's executive director of scientific activities. The
largest percentage of the agency's cash, however, will be going for
“development” – 35 percent or $970 million. Olson defined
“development” as “essentially our IND enabling, our
preclinical development programs and our clinical development
programs.”
Basic research is to receive 17 percent
or about $469 million with buildings and facilities taking up $443
million or 16 percent. Training and career development has consumed
about 15 percent or $414 million.
However, those calculations include
$577 million in funds that have been allocated but not yet awarded.
Another $491 million is “concept approved” but also not awarded.
The agency's governing board could change those allocations or
withdraw approval of concepts, although it has not yet shown signs
that it might do so.
The agency will run out of money for
new grants in 2017 and is examining the possibility of generating
more cash through some sort of public-private partnership. To develop
support for continued funding, the agency is under pressure to
generate results that will resonate with the public and potential
private funding sources. Those results are most likely to come from
a late stage translational/clinical trial effort.
Here is a link to CIRM's translational portfolio as of September 2012.

(An earlier version of this item incorrectly said that the agency would run out of money for new grants in 2013. The correct year is 2017,.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/gzZM85Gu0ME/california-stem-cell-agency-spending.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Stem Cell Agency Spending: Where the Money Is Going

Flim-Flam Stem Cell Artists Targeted by CIRM

Posted: August 25, 2013 at 2:57 am

The California stem cell agency has
joined with other prestigious stem cell organizations to help put a
stop to the flim-flam artists that prey on desperate people by
promising miracle cures from stem cell treatments.
The agency announced the action today on its blog, declaring that it has posted a new patient advisory document that provides a “ robust and detailed set of issues
patients should consider when making treatment decisions.”
Don Gibbons, CIRM's senior science and
education communications officer and author of the blog item, said
the document addresses one of his special concerns: Internet “ads
that come up on web searches and seem to be offering everything to
everyone.”
Some of those ads can be found on many stem cell-related web sites, including this one, that carry ads that are placed there
automatically by Google.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/MsXTjRpEcFY/flim-flam-stem-cell-artists-targeted-by.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Flim-Flam Stem Cell Artists Targeted by CIRM

California Stem Cell Researchers to Receive $70 Million Next Week

Posted: August 25, 2013 at 2:57 am

The California stem cell agency is
scheduled to give away $70 million next week as it moves forward on
its efforts to turn research into cures.
As many as 20 grants and loans are
projected to be awarded in the early translation round. The awards will range up to $3.5 million over a three year period.  The round was open to
both businesses and academic institutions. Collaborators from Germany
were involved, although funding for research in that country is not provided by the state stem cell agency.
The applications will come before
the $3 billion agency's governing board at its Aug. 28 meeting in La Jolla. After next week's awards, the agency, which is known as CIRM,  will have about $500
million left to hand out before cash for new awards runs out in 2017.
The agency is currently examining ways to continue its awards with
some sort of public-private partnership.
Also on the board's agenda is a
proposed announcement for a CIRM/industry co-funding agreement. No
further details on that program were available early today on the agenda.
Other matters to be considered include final approval of the changes
in the agency's IP regulations, appointment of new members to the
grant review group and the latest report on the outside contracts
held by the agency. Details on those matters are yet to be posted by
the agency.
A tribute to the late Duane Roth,
co-vice chairman of the agency, is also scheduled. The board will
additionally meet behind closed doors to evaluate the performance of
CIRM President Alan Trounson.
The California Stem Cell Report will
carry more information on the meeting as it becomes available.
In addition to the La Jolla location
for the meeting, other locations where the public can take part in
the meeting are in Menlo Park and Duarte. Specific addresses can be
found on the agenda.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/rt53_NIUkj8/california-stem-cell-researchers-to.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Stem Cell Researchers to Receive $70 Million Next Week

Jeunesse™ Stem Cells Latest Technology – Video

Posted: August 24, 2013 at 2:41 am


Jeunesse trade; Stem Cells Latest Technology
More Info at : http://bit.ly/13BSdLS Based on the latest available technology, LUMINESCE trade; cellular rejuvenation serum makes a powerful debut as the first ant...

By: Jeunesse Youthful Secret

Continued here:
Jeunesse™ Stem Cells Latest Technology - Video

Posted in Stem Cell Videos | Comments Off on Jeunesse™ Stem Cells Latest Technology – Video

Stem cells treatment for Cerebral Palsy A1 Medical Center – Video

Posted: August 24, 2013 at 2:41 am


Stem cells treatment for Cerebral Palsy A1 Medical Center
Video documentation of stem cell therapy patient, Faaris Kutty, who received two stem cell treatments at the one of A1 Medical Center for cerebral palsy. Aft...

By: A1MedicalCenter

Read more:
Stem cells treatment for Cerebral Palsy A1 Medical Center - Video

Posted in Stem Cell Videos | Comments Off on Stem cells treatment for Cerebral Palsy A1 Medical Center – Video

Teachers TV: Stem Cell Research: The Lesson – Video

Posted: August 24, 2013 at 2:41 am


Teachers TV: Stem Cell Research: The Lesson
Crown Copyright. Provided by The Academic Grid http://tag.ac/ Further resources available on http://tag.ac Licensed to The Academic Grid formerly The Artis...

By: ACLChannel0

Read the original here:
Teachers TV: Stem Cell Research: The Lesson - Video

Posted in Stem Cell Research | Comments Off on Teachers TV: Stem Cell Research: The Lesson – Video

Stem Cells and Stroke

Posted: August 23, 2013 at 7:46 pm

MIAMI, Fla.

Each year 700 thousand people suffer a stroke in the United States. Until now, the only recovery for paralysis brought on by the stroke was lengthy rehabilitation. Now, a new stem cell therapy is helping stroke patients move again.

James Anderson is a tri-athlete and physical education teacher. He was visiting Florida from Maine when suddenly, I started to feel a little dizzy a little tingling in my right hand and ah I ended up having a stroke, James Anderson told Ivanhoe.

James did not respond to clot busting medication or blockage treatments. So he became paralyzed on the left side of his body. Neurologist Doctor Dileep R. Yavatal treated him as part of a clinical trial, where some of the patients were treated with their own stem cells. While Anderson doesnt know if he was injected with his own stem cells, two months after treatment, Anderson said, "I have had more movement and strength in my legs."

For the clinical trial, stem cells must be injected into the brain no later than two weeks after the stroke occurs. James is now able to move around with a walker, during rehab, and hopes to be able to compete in a triathalon again.

See the rest here:
Stem Cells and Stroke

Posted in Stem Cells | Comments Off on Stem Cells and Stroke

Page 2,278«..1020..2,2772,2782,2792,280..2,2902,300..»